Effect of Infrared Light on Chronic Renal patients undergoing hemodialysis and conservative treatment

Effect of Photobiomodulation with Infrared Led in Chronic Renal dialysis and non-dialysis patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

REBEC

Registry ID

RBR-7gwwxzg

Enrollment

Registered

2025-01-07

Start date

2023-01-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal Insufficiency, Chronic Chronic Disease

Interventions

This is a prospective, cross-sectional, analytical, and descriptive study employing a qualitative approach. The study will be conducted at a renal replacement therapy center and will involve two group

patients will be irradiated for 15 minutes a day, three times a week, for 60 days. Prior to starting the LED light protocol, patients will undergo baseline tests—including complete blood count, urea,

Eligibility

Age

25 Years to 78 Years

Inclusion criteria

Inclusion criteria: chronic kidney disease; both genders; age between 25 and 78 years

Exclusion criteria

Exclusion criteria: aged under 25 or over 78 years; debilitated; those who do not sign the informed consent form

Design outcomes

Primary

Measure	Time frame
Expected outcome 1: To evaluate the effect of infrared LED photobiomodulation on changes in chronic kidney disease stages and on the improvement of anemia in patients with kidney disease. To this end, a photobiomodulation device—referred to as an LED vest—will be used; this device consists of an irradiation system comprising an array of 300 LEDs (940 nm).;Outcome 1: Photobiomodulation (PBM) with infrared LED was not effective in reversing the anemia, as it is a chronic disease involving impaired erythropoietin production resulting from renal dysfunction.;Expected outcome 2: To analyze the systemic effect of photobiomodulation on biochemical components in patients with renal disease following the application of the LED vest, comparing results between patients undergoing dialysis and those receiving conservative treatment.;Outcome 2: FMB induced a significant reduction in pre- and post-dialysis serum urea (p<0.05), increased PRU (%) (p<0.05), and reduced pre- and post-dialysis BUN. Thus, FMB promoted urea clearance in patients with renal disease undergoing renal replacement therapy. In addition to contributing to the quality of hemodialysis provided to patients—maintaining a Kt/V above 1.2 and PRU above 65%—these findings are significant because the removal of serum urea and BUN may contribute to reducing oxidative stress and the chronic inflammatory process. The other hematological parameters showed no significant difference following LED application.;Expected outcome 3: To evaluate the quality of life of patients with chronic kidney disease undergoing the LED treatment protocol.;Outcome 3: It was not possible to assess the quality of life of patients undergoing the LED treatment protocol, as the comparative questionnaire was not administered prior to the start of LED therapy.	—

Measure

Time frame

Expected outcome 1: To evaluate the effect of infrared LED photobiomodulation on changes in chronic kidney disease stages and on the improvement of anemia in patients with kidney disease. To this end, a photobiomodulation device—referred to as an LED vest—will be used; this device consists of an irradiation system comprising an array of 300 LEDs (940 nm).;Outcome 1: Photobiomodulation (PBM) with infrared LED was not effective in reversing the anemia, as it is a chronic disease involving impaired erythropoietin production resulting from renal dysfunction.;Expected outcome 2: To analyze the systemic effect of photobiomodulation on biochemical components in patients with renal disease following the application of the LED vest, comparing results between patients undergoing dialysis and those receiving conservative treatment.;Outcome 2: FMB induced a significant reduction in pre- and post-dialysis serum urea (p<0.05), increased PRU (%) (p<0.05), and reduced pre- and post-dialysis BUN. Thus, FMB promoted urea clearance in patients with renal disease undergoing renal replacement therapy. In addition to contributing to the quality of hemodialysis provided to patients—maintaining a Kt/V above 1.2 and PRU above 65%—these findings are significant because the removal of serum urea and BUN may contribute to reducing oxidative stress and the chronic inflammatory process. The other hematological parameters showed no significant difference following LED application.;Expected outcome 3: To evaluate the quality of life of patients with chronic kidney disease undergoing the LED treatment protocol.;Outcome 3: It was not possible to assess the quality of life of patients undergoing the LED treatment protocol, as the comparative questionnaire was not administered prior to the start of LED therapy.

—

Secondary

Measure	Time frame
No secondary outcomes were expected.	—

Countries

Contacts

Public ContactMariane Ferreira

Universidade Anhembi Morumbi

mariane.lopess@hotmail.com+55-93-991842010

Outcome results

None listed

Source: REBEC (via WHO ICTRP) · Data processed: Aug 10, 2026